Selective Pressure-Regulated Retroinfusion for Gene Therapy Application in Ischemic Heart Disease.

about

Selective Pressure-Regulated Retroinfusion for Gene Therapy Application in Ischemic Heart Disease.

Item

http://www.wikidata.org/entity/Q45862456

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Selective Pressure-Regulated R ...... ion in Ischemic Heart Disease.

@en

Selective Pressure-Regulated R ...... ion in Ischemic Heart Disease.

@nl

type

Item

label

Selective Pressure-Regulated R ...... ion in Ischemic Heart Disease.

@en

Selective Pressure-Regulated R ...... ion in Ischemic Heart Disease.

@nl

prefLabel

Selective Pressure-Regulated R ...... ion in Ischemic Heart Disease.

@en

Selective Pressure-Regulated R ...... ion in Ischemic Heart Disease.

@nl

P1476

Selective Pressure-Regulated R ...... ion in Ischemic Heart Disease.

@en

P2093

Rabea Hinkel

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model

MRTF-A controls vessel growth and maturation by increasing the expression of CCN1 and CCN2.

AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model

Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine.

Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection

Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Gene therapy for ischemic heart disease.

Adjuvant early and late cardioprotective therapy: access to the heart.

Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis.

P304

249-260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/978-1-4939-6588-5_18

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

1521

http://www.w3.org/2001/XMLSchema#string

P50

Christian Kupatt

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27910055

http://www.w3.org/2001/XMLSchema#string